Examiner: SWARTZ, Rodney P.

Art Unit: 1645

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

a 2006 Application of:

Pato et al.

Frial No.:

10/715,591

Filed:

November 18, 2003

Entitled:

NOVEL THERAPEUTIC TARGETS FOR

THE TREATMENT OF MYCOBACTERIAL INFECTIONS AND COMPOUNDS USEFUL

**THERFOR** 

Attorney Docket No.: GPC-012.3 US

**Mail Stop AMENDMENT** 

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Sir:

Transmitted herewith are: [X] an Information Disclosure Statement (IDS) under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] photocopies of the disclosed documents, to be filed in the above-identified patent application; and [X] a return receipt post card.

#### PAYMENT OF FEES

- [ ] A check in the amount of \$\_\_\_\_ (check no. ) in payment of the fee for submission of an information disclosure statement transmitted herewith.
- [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR §§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Michael R. Wesolowski, Reg. No. 50,944

Leon R. Yankwich, Reg. No. 30,237

Attorneys for Applicants

YANKWICH & ASSOCIATES

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700 telefax: (617) 374-0055

U.S. Serial No. 10/715,91 (Atty. Docket No. GPC-012.3 US)



### **CERTIFICATE OF MAILING**

The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

10/17/2006

Meghan F. McFadden



Art Unit: 1645

Examiner: SWARTZ, Rodney P.

Application

Pato et al.

Serial No.:

10/715,591

Filed:

November 18, 2003

Entitled:

**NOVEL THERAPEUTIC TARGETS** 

FOR THE TREATMENT OF

**MYCOBACTERIAL INFECTIONS** AND COMPOUNDS USEFUL

**THERFOR** 

Attorney Docket No.: GPC-012.3 US

### **Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents. This Statement is being submitted before the first Office Action on the merits pursuant to 37 C.F.R. § 1.97(b)(3). Accordingly, no fee is required with this submission.

# Foreign Published Applications

WO 99/46267, published September 16, 1999, Nordisk

WO 01/98290, published December 27, 2001, Pharmacia Italia S.P.A.

WO 02/094796, published November 28, 2002, Axxima Pharmaceuticals AG

U.S. Serial No. 10/715,91 (Atty. Docket No. GPC-012.3 US)

#### **Other Documents**

Arruda et al., Science, 261: 1454-1457 (1993)

Braunstein et al., J. Bacteriol, 182(10): 2732-2740 (2000)

Koul et al., Microbiology, 147: 2307-2314 (2001)

Mundayoor et al., Ann. N.Y. Acad. Sci., 730: 26-36 (1994)

Peirs et al., Eur. J. Biochem., 244(2): 604-612 (1997)

Wei et al., J. Bacteriol., 182: 377-384 (2000)

Wieles et al., Infect. Immun., 65(7): 2537-2541 (1997)

Zahrt et al., Proc. Natl. Acad. Sci., 98(22): 12706-12711 (2001)

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application, and also printed on any patent issuing from the above-identified application.

Respectfully submitted,

mill Wash h.

Michael R. Wesolowski, Reg. No. 50,944

Leon R. Yankwich, Reg. No. 30,237

Attorneys for Applicants

YANKWICH & ASSOCIATES, P.C.

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700

telefax: (617) 374-0055



U.S. Serial No. 10/715,91 (Atty. Docket No. GPC-012.3 US)

# **Certificate of Mailing**

The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

10/17/2006

3

Modified FORM PTO-1449	ATTY. DOCKET NO. GPC-012.3 US	<b>SERIAL NO.</b> 10/715,591
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pato et al.	
OCT 19 2006 USe several sheets if necessary)	FILING DATE November 18, 2003	<b>GROUP</b> 1645

RECERCIÓN DESIGNATION

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	Subclass	TRANS YES	LATION NO
AA	WO 99/46267	09/19/1999	Nordisk				
AB	WO 01/98290	12/27/2001	Pharmacia Italia S.P.A.				
AC	WO 02/094796	11/28/2002	Axxima Pharmaceuticals				
			AG				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AD	Arruda et al., <i>Science</i> , 261: 1454-1457 (1993)			
	AE	Braunstein et al., J. Bacteriol, 182 (10): 2732-2740 (2000)			
	AF	Koul et al., Microbiology, 147: 2307-2314 (2001)			
	AG	Mundayoor et al., Ann. N.Y. Acad. Sci., 730: 26-36 (1994)			
	AH	Peirs et al., Eur. J. Biochem., 244 (2): 604-612 (1997)			
	AI	Wei et al., J. Bacteriol., 182: 377-384 (2000)			
	AJ	Wieles et al., Infect. Immun., 65 (7): 2537-2541 (1997)			
	AK	Zahrt et al., Proc. Natl. Acad. Sci., 98 (22): 12706-12711 (2001)			
CCV	7				
EXAMINER		ER	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

-					
sh	$\sim$	+	1	of	1
211		L		VI.	